Navigation Links
Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C
Date:10/10/2011

PRINCETON, N.J., Oct. 10, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the addition of two treatment arms to the ELECTRON trial of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The rapid and consistent antiviral effects and high barrier to resistance demonstrated with PSI-7977 to date provided the rationale for additional exploratory regimens in this setting.  The protocol amendment adds one arm exploring 12 weeks of PSI-7977 monotherapy in treatment naive patients with HCV genotype 1 (GT1), and one arm of PSI-7977 and ribavirin (RBV) in treatment-experienced patients with HCV genotype 2 (GT2) or genotype 3 (GT3).  In addition, the previously announced arm in HCV GT1 patients with a prior "null" response to an interferon (IFN) containing regimen, which was planned to assess PSI-7977/IFN/RBV, has been modified to an IFN-free 12-week regimen of PSI-7977/RBV.

"We look forward to reporting SVR12 results from Part 1 and interim data from the PSI-7977 monotherapy arm of ELECTRON on Sunday, November 6th, 2011 at the upcoming 2011 American Association for the Study of Liver Diseases (AASLD) annual meeting.  The preliminary results to be discussed at AASLD led us to expand the study to add an arm of PSI-7977 monotherapy for HCV GT1," said Michelle Berrey, MD, MPH, Pharmasset's Chief Medical Officer.  "We and others continue to explore the potential of PSI-7977 for IFN-free and monotherapy treatment regimens in a broader group of individuals living with HCV of all genotypes and regardless of their response to prior treatment."

In addition to previously announced interferon-free studies of PSI-7977 by Bristol Myers Squibb and Tibotec, The National Institute of Health (NIH) recently initiated an interferon-free 24 week study of PSI-7977 400mg QD with and without ribavirin, in 60 treat
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset to Present at Two Upcoming Conferences
2. Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
3. Pharmasset Announces Two-for-One Forward Stock Split
4. Pharmasset to Present at Canaccord Genuity Growth Conference
5. Pharmasset Reports Fiscal Third Quarter 2011 Financial Results
6. Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
7. Pharmasset to Present at Two Upcoming Investor Conferences
8. Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
9. Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
10. Pharmasset to Webcast an Investor Event From the EASL Meeting
11. Pharmasset to Present at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... ROCKY HILL, Conn. , June 18, 2013 ... many past clients of Alliance Seating and Mobility, ... now unable to access timely repair. This appears ... and a dramatic reduction of field service employees.  ... Unfortunately a great many of these clients ...
(Date:6/18/2013)... June 18, 2013  Cataracts are the leading cause ... Association of Ophthalmology, aging is the leading cause of ... eye,s natural lens. 22 million Americans age 40 and ... continue to age, that number will increase over 30 ... iPhones, iPads, smart-phones and computers, the demographic of ages ...
(Date:6/18/2013)... 2013  Decision Resources, one of the world,s ... healthcare issues, announces that its Market Access Tracker ... Middle East and Africa ... and opportunities to gaining and maintaining favorable market ... countries. The countries covered by Market Access Tracker ...
Breaking Medicine Technology:New Vision Hope For Millions Undergoing Cataract Surgery 2New Vision Hope For Millions Undergoing Cataract Surgery 3Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 3
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) will host investors ... an in depth discussion on the current management of Clostridium ... webcast of the event beginning at 9:00 a.m. ET will be ... www.optimerpharma.com . A replay will be available for 90 days. ...
... Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals ... Chief Executive Officer, will present at the Lazard ... St. Regis hotel in New York City on ... About Omthera Pharmaceuticals, Inc.Founded in ...
Cached Medicine Technology:Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18 2
(Date:6/19/2013)... York, NY (PRWEB) June 19, 2013 Men ... and do not pay close attention to what they are ... here in June, the leading producer and supplier of Siberian ... stomach ulcers of the all-natural healing elements within ... peptic ulcers, are the most common ulcers within the gastrointestinal ...
(Date:6/19/2013)... 2013 Recovery Associates, through its multiple ... addiction treatment, helping men and women break free from ... meth is a stimulant named for the crystalline structure ... commonly smoked, but it can also be injected or ... homemade labs using common household ingredients and over-the-counter medicine. ...
(Date:6/19/2013)... 2013 Best Halfway House is stretching its ... chance to keep on their road of recovery from drug ... of selections for sober houses for men and women. , ... network need to meet certain criteria. They have to be ... must have structure and accountability measures in place. This ensures ...
(Date:6/19/2013)... The Mesothelioma Victims Center says, "According ... to 3000 citizens, who will be diagnosed with a ... one third will be US Navy Veterans. We can ... exposure form of cancer, or their family members that ... most skilled mesothelioma compensation settlement attorneys, who actually do ...
(Date:6/19/2013)... National Camp Series (NCS) Associate Dan Zeidman, ... effort to fight ovarian cancer according to NFL Kicker, and ... excited to have Dan jump on board,” says Cundiff. “He ... great example, great purpose. That is exactly what we are ... Kicking For The Dream is definitely a project ...
Breaking Medicine News(10 mins):Health News:Pine Nut Oil is a Proven Remedy for Stomach Ulcers 2Health News:Crystal Meth Addiction Treatment and Crystal Meth Drug Rehab Announced by Recovery Associates 2Health News:Pensacola, Florida Joins Best Halfway House Recovery Network, Providing Resources for Those Seeking to Further Their Recovery from Drug and Alcohol Addiction 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 3Health News:National Camp Series (NCS) Associate Dan Zeidman of Lifetime Kicking Academy Joins Kicking For The Dream’s Effort to Fight Ovarian Cancer 2Health News:National Camp Series (NCS) Associate Dan Zeidman of Lifetime Kicking Academy Joins Kicking For The Dream’s Effort to Fight Ovarian Cancer 3
... , WEDNESDAY, Nov. 30 (HealthDay News) -- ,Patients ... exams if the tests are ordered by doctors with ... a new study. In order to scrutinize this ... ordered by two orthopedic physician groups in the same ...
... Publicly posting enforcement and testing data corresponding to specific ... Internet could have "substantial benefits," including the potential to ... the National Research Council. The report adds that ... transparency and yield valuable insights that go beyond the ...
... November 30, 2011 From targeted cancer chemotherapy ... century may prove to be the age of big ... be miniscule. Experts in chemistry, applied physics, materials ... the BASF Advanced Research Initiative at Harvard University,s symposium ...
... research suggests that a calorie-restricted diet higher in proteinmostly ... exercise has a major positive impact on bone health ... study, published online in the Journal of Clinical ... particularly evident due to the high density of bone-supporting ...
... reason why "an apple a day keeps the doctor ... Journal of Leukocyte Biology (https://www.jleukbio.org), oral ingestion of ... T cell activation to prevent colitis in mice. This ... T cells in polyphenol-mediated protection against an autoimmune disease ...
... , WEDNESDAY, Nov. 30 (HealthDay News) -- New research ... young athlete,s brain that may last longer than thought. ... sports-related concussions, the majority experienced immediate decreased blood flow ... compared to non-injured athletes after two weeks, and one-quarter ...
Cached Medicine News:Health News:Docs Who Own MRIs Order Far More Scans 2Health News:Publicly releasing inspection data on meat processing facilities could have 'substantial benefits' 2Health News:Publicly releasing inspection data on meat processing facilities could have 'substantial benefits' 3Health News:Nano meets pharma at Harvard-BASF symposium 2Health News:Nano meets pharma at Harvard-BASF symposium 3Health News:Dieters should eat foods rich in protein, mostly from dairy, to protect bones during weight loss 2Health News:Scientists discover anti-inflammatory polyphenols in apple peels 2Health News:Recovery From Concussions in Young Athletes May Take Longer Than Thought 2Health News:Recovery From Concussions in Young Athletes May Take Longer Than Thought 3Health News:Recovery From Concussions in Young Athletes May Take Longer Than Thought 4
... Humphrey GPA software accurately differentiates clinically ... from random variability, providing an advanced, ... glaucoma for your patients. , ,The ... multi-center clinical trial, in which the ...
... non-mydriatic fundus camera increases ... of fundus imaging. Compact, ... set the standard in ... a unique combination of ...
... test and the fully automated ... facts conveniently available when and ... the patient can be carried ... Test Cartridge contains all reagents ...
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
Medicine Products: